ACHCNasdaqServices-Specialty Outpatient Facilities, NECFiscal year ends December 31
Acadia Healthcare Company, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$30.18+0.20 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $2.74B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
-33.3%−1.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.0% | +8.3% | +9.7% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 0.3% | -30.5% | -43.9% | |
| Return on assets | 0.1% | -10.0% | -19.2% | |
| Current ratio | 1.25 | 1.93 | 1.55 | |
| Debt to equity | 1.52 | 1.64 | 1.28 | |
| Net debt to EBITDA | 4.34× | – | – | |
| Capex to revenue | 10.9% | 10.8% | 17.3% | |
| Diluted shares | 86M | 89M | 91M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Acadia Healthcare generated $1.48B from operations and spent $2.28B on capital expenditure, dividends and share buybacks. 98% of that went back into the business.
Generated
$1.48B
Used
$2.28B
Capital expenditure$2.23B98%Dividends$00%Share buybacks$50.03M2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-33.3%
×Asset turnover0.58×
×Equity multiplier2.29×
=Return on equity, FY2025-43.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -33.3% | 0.58× | 2.29× | -43.9% |
| FY2024 | 8.1% | 0.56× | 1.93× | 8.7% |
| FY2023 | -0.7% | 0.57× | 1.85× | -0.8% |
| FY2022 | 10.5% | 0.54× | 1.83× | 10.2% |
| FY2021 | 8.2% | 0.41× | 2.55× | 8.6% |
| FY2020 | -32.2% | 0.31× | 3.04× | -30.5% |
| FY2019 | 5.4% | 0.31× | 2.70× | 4.5% |
| FY2018 | -9.2% | 0.30× | 2.57× | -7.2% |
| FY2017 | 7.0% | 0.46× | 2.63× | 8.4% |
| FY2016 | 0.2% | 0.55× | 2.68× | 0.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.10B
- Cash generatingOperating cash flow above zero$131.90M
- Return on assets improvedROA up on the prior year4.8% → -18.5%
- Earnings backed by cashOperating cash flow above net income$131.90M vs -$1.10B
- Less leverageLong-term debt to assets fell31.6% → 44.7%
- Better liquidityCurrent ratio rose1.00 → 1.55
- No dilutionShare count did not rise92M → 91M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.59 → 0.56